"Anticarcinogenic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved.
| Descriptor ID |
D016588
|
| MeSH Number(s) |
D27.505.696.706.018 D27.505.954.248.125 D27.720.799.018
|
| Concept/Terms |
Anticarcinogenic Agents- Anticarcinogenic Agents
- Agents, Anticarcinogenic
- Anti-Carcinogenic Drugs
- Anti Carcinogenic Drugs
- Drugs, Anti-Carcinogenic
- Anticarcinogens
- Anti-Carcinogenic Agents
- Agents, Anti-Carcinogenic
- Anti Carcinogenic Agents
- Anticarcinogenic Drugs
- Drugs, Anticarcinogenic
Anticarcinogenic Effect- Anticarcinogenic Effect
- Effect, Anticarcinogenic
- Anti-Carcinogenic Effects
- Anti Carcinogenic Effects
- Effects, Anti-Carcinogenic
- Anticarcinogenic Effects
- Effects, Anticarcinogenic
- Anti-Carcinogenic Effect
- Anti Carcinogenic Effect
- Effect, Anti-Carcinogenic
|
Below are MeSH descriptors whose meaning is more general than "Anticarcinogenic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticarcinogenic Agents".
This graph shows the total number of publications written about "Anticarcinogenic Agents" by people in this website by year, and whether "Anticarcinogenic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 1 | 4 |
| 1995 | 4 | 1 | 5 |
| 1996 | 7 | 0 | 7 |
| 1997 | 9 | 1 | 10 |
| 1998 | 4 | 1 | 5 |
| 1999 | 11 | 2 | 13 |
| 2000 | 16 | 3 | 19 |
| 2001 | 22 | 4 | 26 |
| 2002 | 11 | 2 | 13 |
| 2003 | 18 | 4 | 22 |
| 2004 | 10 | 3 | 13 |
| 2005 | 13 | 2 | 15 |
| 2006 | 14 | 3 | 17 |
| 2007 | 12 | 6 | 18 |
| 2008 | 7 | 2 | 9 |
| 2009 | 6 | 5 | 11 |
| 2010 | 10 | 2 | 12 |
| 2011 | 9 | 3 | 12 |
| 2012 | 7 | 1 | 8 |
| 2013 | 3 | 1 | 4 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 2 | 3 | 5 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 1 | 3 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticarcinogenic Agents" by people in Profiles.
-
Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models? J Nutr. 2022 06 09; 152(6):1381-1403.
-
Non-Aspergillus invasive mould infections in patients treated with ibrutinib. Mycoses. 2020 Aug; 63(8):787-793.
-
Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. Cancer Prev Res (Phila). 2020 06; 13(6):497-508.
-
Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help? Future Oncol. 2020 Mar; 16(9):413-415.
-
Genistein Prevents Development of Spontaneous Ovarian Cancer and Inhibits Tumor Growth in Hen Model. Cancer Prev Res (Phila). 2019 03; 12(3):135-146.
-
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44.
-
Sensory acceptable equivalent doses of ?-phenylethyl isothiocyanate (PEITC) induce cell cycle arrest and retard the growth of p53 mutated oral cancer in vitro and in vivo. Food Funct. 2018 Jul 17; 9(7):3640-3656.
-
Natural history of colonic polyposis in young patients with familial adenomatous polyposis. Gastrointest Endosc. 2018 10; 88(4):726-733.
-
Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol. Int J Cancer. 2018 04 01; 142(7):1405-1417.
-
Oral bexarotene for post-transplant cutaneous T-cell lymphoma. Dermatol Ther. 2017 Sep; 30(5).